Several recent laboratory studies of cannabidiol, or CBD, have shown promising results in the context of prevention the coronavirus infection.
The study performed by the team of Marsha Rosner of the University of Chicago (USA) recently published evidence that CBD could block the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) responsible for COVID-19.
Their study published in scientific journal “Science Advances” has shown that non-toxic doses of highly purified CDB is insufficient to block the infection of SARS-CoV-2 but could be enough to block its replication at early and even later stages of infection. One of the mechanisms contributing to the antiviral activity of CBD is the induction of the interferon pathway both directly and indirectly following by the activation of the host immune response to the viral pathogen.
They additionally checked if the closely related CBD congeners and analogues with closely related structures and polarities produced by the hemp plant (THC, cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabichromene (CBC), or cannabigerol (CBG)) could also exhibits antiviral activity of SARS-CoV-2. Furthermore, the combination of THC with CBD prevents the CBD’s action.
The authors of the study discourage the “use of non-medical formulation including edibles, inhalants or topicals as a preventative or treatment therapy”. CBD-medical products have become widely available in many countries including Switzerland, where with a prescription patients can get a treatment with THC > 1%.
If you are interested to know more about cannabinoids, please check our website: